Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.
beasleynmny

Inplay From Briefing.com - Yahoo Finance

The 2019 notes will bear interest at a rate of 0.25% per year and the 2021 notes will bear interest at a rate of 1.00% per year. Twitter expects to use approximately $112.3 million of the net proceeds http://merlehtkn.wallinside.com of the offering of the notes to pay the cost of the convertible note hedge transaction and to use the remaining proceeds of the offering for general corporate purposes. The initial conversion rate for the 2019 notes is 12.8793 shares of common stock per $1,000 principal amount of notes and the initial conversion rate for the 2021 notes is 12.8793 shares of common stock per $1,000 principal amount of notes. Conversions of the notes will be settled in cash, shares of Twitter's common stock or a combination thereof, at Twitter's election. 9:03 am Wipro enters into a Premier Partnership with Adobe ( ADBE ) ( WIT ) : The co will partner with Adobe (ADBE) in creating integrated marketing, commerce, analytics and customer kim kardashian and kanye west experience solutions.The newly formed business unit, Wipro Digital enables businesses in their Digital Transformation initiatives to adapt and be relevant in the increasingly digital lifestyle of their customers. 9:02 am Teva Pharma announces new scientific data presented at the MS Boston 2014: Joint Actrims-Ectrims meeting reveals differences in the gene expression profile between COPAXONE (glatiramer acetate injection) and http://ciatilofu1y.beeplog.com/303795_4981221.htm other glatiramer acetate products ( TEVA ) : Co announced that new scientific data presented at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting reveals differences in the gene expression profile between COPAXONE (glatiramer acetate injection) and other glatiramer acetate products. In this research, a human monocyte cell line photos of kim kardashian was stimulated by either COPAXONE or another reference glatiramer acetate product from several manufacturers. Differences between the gene expression profiles induced by COPAXONE and these other glatiramer acetate products were observed upon cell stimulation and subsequently confirmed by a quantitative laboratory test. 9:01 am Amarin announces the Office of New Drugs within the FDA has denied co's appeal of FDA's rescission of the ANCHOR clinical trial Special Protocol Assessment agreement ( AMRN ) : Co announced today that the Office of New Drugs within the U.S.
Source: http://finance.yahoo.com/news/inplay-briefing-com-175538006.html

Don't be the product, buy the product!

Schweinderl